Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to -$27.2 million.

  • Northwest Biotherapeutics' Net Income towards Common Stockholders fell 3935.2% to -$27.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$91.2 million, marking a year-over-year decrease of 2845.92%. This contributed to the annual value of -$85.2 million for FY2024, which is 3234.12% down from last year.
  • Northwest Biotherapeutics' Net Income towards Common Stockholders amounted to -$27.2 million in Q3 2025, which was down 3935.2% from -$15.9 million recorded in Q2 2025.
  • Northwest Biotherapeutics' Net Income towards Common Stockholders' 5-year high stood at $213.9 million during Q4 2021, with a 5-year trough of -$32.9 million in Q3 2022.
  • Its 5-year average for Net Income towards Common Stockholders is -$7.0 million, with a median of -$18.3 million in 2024.
  • Data for Northwest Biotherapeutics' Net Income towards Common Stockholders shows a peak YoY increase of 17631.21% (in 2021) and a maximum YoY decrease of 25700.69% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Northwest Biotherapeutics' Net Income towards Common Stockholders stood at $213.9 million in 2021, then plummeted by 113.23% to -$28.3 million in 2022, then surged by 49.4% to -$14.3 million in 2023, then crashed by 99.02% to -$28.5 million in 2024, then grew by 4.61% to -$27.2 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$27.2 million for Q3 2025, versus -$15.9 million for Q2 2025 and -$19.6 million for Q1 2025.